How Big Is Trump’s Big Prescription Drug Plan?

Kevin Drum

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

Last Friday President Trump unveiled four executive orders that he claimed would revolutionize the prescription drug industry. Let’s take a look at three of them:

  • The first order clarifies that discounts under a program for low-income patients should be passed directly on to patients. This is a fine idea, but Trump’s version applies to only a tiny segment of the market.
  • A second order eliminates rebates that drug companies pay to Medicare Part D plans for seniors. In other words, it raises drug prices.
  • The third order allows importation of drugs from Canada. This has been underway for a while, so there was nothing new in Trump’s announcement. What’s more, Canada is still opposed since it wants to make sure Americans don’t cannibalize their supply of drugs.

Taken together, these three executive orders would have only the most modest effect. But how about the fourth order? This one would direct Medicare to base the price it pays for certain drugs to the price paid by foreign countries. In theory this might be a good idea that forces pharmaceutical companies to treat the United States more fairly. But hold your applause: it would apply only to drugs administered by physicians and Trump gave drug companies 30 days to come up with a better plan. There’s a good chance that even this limited proposal will never see the light of day.

I have not been able to find a rigorous analysis of how much these proposals are likely to affect the overall cost of prescription drugs. At a guess, though, the first two are minuscule and cancel each other out. The Canadian reimportation rule will save consumers some money, but not much overall.

So that leaves the “favored nation” rule, which at least has the potential to drive down the cost of certain expensive drugs. Unfortunately, there’s no way of knowing what impact it will have until Trump issues an actual order instead of simply using it as a threat to hold over the heads of the pharma industry—which he’s been doing for the past couple of years with no results. Given the opposition of both pharma and most of the Republican Party, this is a pig in a poke until we see a final order.

AN IMPORTANT UPDATE

We’re falling behind our online fundraising goals and we can’t sustain coming up short on donations month after month. Perhaps you’ve heard? It is impossibly hard in the news business right now, with layoffs intensifying and fancy new startups and funding going kaput.

The crisis facing journalism and democracy isn’t going away anytime soon. And neither is Mother Jones, our readers, or our unique way of doing in-depth reporting that exists to bring about change.

Which is exactly why, despite the challenges we face, we just took a big gulp and joined forces with The Center for Investigative Reporting, a team of ace journalists who create the amazing podcast and public radio show Reveal.

If you can part with even just a few bucks, please help us pick up the pace of donations. We simply can’t afford to keep falling behind on our fundraising targets month after month.

Editor-in-Chief Clara Jeffery said it well to our team recently, and that team 100 percent includes readers like you who make it all possible: “This is a year to prove that we can pull off this merger, grow our audiences and impact, attract more funding and keep growing. More broadly, it’s a year when the very future of both journalism and democracy is on the line. We have to go for every important story, every reader/listener/viewer, and leave it all on the field. I’m very proud of all the hard work that’s gotten us to this moment, and confident that we can meet it.”

Let’s do this. If you can right now, please support Mother Jones and investigative journalism with an urgently needed donation today.

payment methods

AN IMPORTANT UPDATE

We’re falling behind our online fundraising goals and we can’t sustain coming up short on donations month after month. Perhaps you’ve heard? It is impossibly hard in the news business right now, with layoffs intensifying and fancy new startups and funding going kaput.

The crisis facing journalism and democracy isn’t going away anytime soon. And neither is Mother Jones, our readers, or our unique way of doing in-depth reporting that exists to bring about change.

Which is exactly why, despite the challenges we face, we just took a big gulp and joined forces with The Center for Investigative Reporting, a team of ace journalists who create the amazing podcast and public radio show Reveal.

If you can part with even just a few bucks, please help us pick up the pace of donations. We simply can’t afford to keep falling behind on our fundraising targets month after month.

Editor-in-Chief Clara Jeffery said it well to our team recently, and that team 100 percent includes readers like you who make it all possible: “This is a year to prove that we can pull off this merger, grow our audiences and impact, attract more funding and keep growing. More broadly, it’s a year when the very future of both journalism and democracy is on the line. We have to go for every important story, every reader/listener/viewer, and leave it all on the field. I’m very proud of all the hard work that’s gotten us to this moment, and confident that we can meet it.”

Let’s do this. If you can right now, please support Mother Jones and investigative journalism with an urgently needed donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate